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sion: A high consensus of European MQS for treatment/re-
habilitation and harm reduction has been achieved. Further 
implementation and developmental steps are discussed. 
 Copyright © 2013 S. Karger AG, Basel 
 Introduction 
 Why Quality Standards? 
 The Institute of Medicine, an American non-profit, 
non-governmental organisation founded in 1970 under 
the congressional charter of the American National Acad-
emy of Sciences, has defined quality of care as ‘the degree 
to which health services for individuals and populations 
increase the likelihood of desired health outcomes [the 
desired end results of healthcare in terms of benefits to 
the patient and society] and are consistent with current 
professional knowledge’  [1] . Good quality means provid-
ing patients with appropriate services in a technically 
competent manner with good communication, shared 
decision-making, and cultural sensitivity  [2] .
 In our understanding, the quest for treatment quality 
in the drug field is based on the following economic, eth-
ical and political motivations: poor quality services are 
ineffective and a waste of economic resources; patients’ 
rights necessitate effective interventions and safety stan-
dards (the principle of non-maleficence is still valid). 
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 Abstract 
 Background/Aims: The Study on the Development of an EU 
Framework for Minimum Quality Standards and Benchmarks 
in Drug Demand Reduction (EQUS) has set up an inventory 
of quality standards and initiated a consensus-building pro-
cess, aiming at establishing a set of European minimum 
quality standards (MQS) for treatment/rehabilitation and 
harm reduction in the field of drug abuse and dependence. 
 Methods: Existing documents were collected by country-
specific experts and integrated into a predefined framework 
of quality standards. Agreement, implementation status and 
expected implementation problems of the proposed stan-
dards were assessed by a survey of European stakeholders 
and the final lists of European MQS were established at a Eu-
ropean conference.  Results: Overall, 349 documents were 
identified as relevant. Major gaps were identified for ethical 
and legal standards, and for documents that provide grades 
of evidence for specific standards. A high level of acceptance 
was found for the treatment/rehabilitation MQS, while a 
somewhat lower level was found for the harm reduction 
MQS. The final lists of MQS were based on at least 80% of ac-
ceptance by European experts and stakeholders.  Conclu-
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However, recent research findings show that severe defi-
ciencies in treatment quality exist despite these concerns. 
A study on a representative sample of substance abuse 
services in the USA documented low professional status 
and a severe lack of competence due to high staff turnover 
 [3] . A study on the management of high-risk opioid ad-
dicts in EU member states documented a major need for 
improvements in all treatment centres despite significant 
differences between centres  [4] .
 One way to improve the quality of service is to intro-
duce clinical guidelines, but guidelines do not always pro-
vide reliable guidance. A review of 28 national guidelines 
for opioid substitution therapy documented a range of 
inappropriate restrictions without an evidence base, such 
as a minimum duration of dependence of 3 years before 
starting opioid substitution therapy or for example a min-
imum age of >25 years. The review found major incon-
gruity among guidelines concerning settings, indication 
rules, dosage schemes, controls, funding and quality 
management  [5] .
 Another improvement strategy is the utilisation of 
 systematic training programmes, including best practice 
guidance. An ongoing example is the TREATNET proj-
ect, which engaged staff from 20 resource centres in 19 
countries in a comprehensive training programme and 
set up workgroups to produce best practice papers on 
specific issues  [6] .
 Why Minimum Quality Standards? 
 Another approach involves the effort to define mini-
mum quality standards that would be affordable under 
the conditions of financial constraint and scarcity of ad-
diction specialists. Minimum quality standards can serve 
as indicators of relevant deficits in service provision and 
facilitate the accountability of services and staff, and these 
minimum standards can be instrumental for priority set-
ting in service improvement and related research.
 The WHO engaged in such efforts early on. In 1992, 
the WHO published standards of care in drug abuse 
 treatment  [7] . Later, WHO included methadone and 
 buprenorphine as medications for the maintenance 
 treatment of opiate dependence in the list of essential 
medicines  [8] and combined evidence-based recommen-
dations for best practice in opioid substitution treatment 
with a range of recommended minimum requirements 
related to legal, clinical, procedural and ethical issues  [9] .
 One of the first European efforts to collect systematic 
information and to establish qualitative norms for the 
care of drug abusers was focused on professional stan-
dards, ethical standards, a needs assessment, an evalua-
tion of effectiveness and an economic evaluation  [10] . 
The effort resulted in the formulation of guidelines, as-
sessment procedures and checklists for each domain.
 How to Determine (Minimum) Quality Standards 
 A crucial question concerns the methods and the cri-
teria for defining quality standards. Some methods have 
been implemented, such as establishing guidelines for 
guidelines  [11] , a system to determine the evidence of ef-
fectiveness (e.g. the GRADE model  [12] ), or systematic 
expert consensus (e.g. the AGREE model  [13] ).
 Each of these approaches has its merits and its limita-
tions. Deficiencies of guidelines mainly concern a poor 
inter-observer reliability in interpretation of the guide-
lines, a limited applicability of recommendations, an in-
complete specification of exceptions that may require de-
viations from the guidelines, and frequently unknown ef-
fects on patient outcomes  [14] . Additionally, it is possible 
that the expected outcomes as predicted by efficacy stud-
ies will not be attained when implemented under field 
conditions  [15] and in different socio-cultural settings. 
The GRADE system gives randomised controlled studies 
the highest grade, but they are not applicable for many 
structural and procedural quality standards. Moreover, 
results from randomised controlled studies are only of 
limited relevance for many more complex patients’ drug 
problems in real-life treatment situations. 
 The Study on the Development of an EU Framework 
for Minimum Quality Standards and Benchmarks in 
Drug Demand Reduction (EQUS) made an attempt to 
combine these approaches. The study collected relevant 
guidelines and other documents from all EU member 
states and extracted from those a set of minimum quality 
standards for interventions, services and treatment sys-
tems, and harm reduction approaches.
 How to Find Consensus 
 To find a consensus in which quality indicators are 
relevant for the formulation of substance abuse treatment 
is challenging. Harm reduction guidelines or standards 
can be difficult to implement on a national level, and even 
more so across several countries, as would be the case for 
European guidelines and standards. Top-down introduc-
tion and the implementation of evidence-based medicine 
in the treatment of substance abuse disorders is at risk of 
failure in many domains. One prominent example of 
such a failure was the Quality Enhancement Research Ini-
tiative from the US Veterans Health Administrations  [16] 
that did not account, according to its own reports  [17] , 
for the local conditions and opinions of local leaders, and 
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did not allow for the creation of networking opportuni-
ties to enhance stakeholder interactions and maintain en-
thusiasm in the programme. On a local level, top-down 
implementation processes can be more successful. For 
example, the top-down implementation, from research to 
practice, of an evidence-based treatment for substance 
abuse disorders and total quality management as a funda-
mental process redesign programme in a large Dutch ad-
diction treatment centre was a remarkable success  [18] . 
 Historically, detailed reflections, explanations and 
models of consensus-building processes stem from large 
multicultural parliamentary authorities  [18] . The Delphi 
method, a method that uses expert judgements and com-
pares these judgements with the aggregate judgements of 
other participating experts until a consensus is reached 
 [19] , was introduced in the early 1970s to social policy 
and public health consensus-building processes and was 
also used to reach a consensus on drug policy priorities 
 [20] in the USA in 1973. The concept of targeting a large 
population for a Delphi method-based consensus process 
with the assistance of internet-based survey methods was 
first described in 2001  [21] .
 Aims of the EQUS Study 
 The EQUS study aimed to document existing stan-
dards, guidelines and other relevant documents on qual-
ity in treatment, rehabilitation, and harm reduction with-
in the EU member states and at the international level. It 
also aimed to screen this documentation for relevance 
and then set up a comprehensive inventory of quality 
standards and guidelines in the field of drug demand re-
duction. Moreover, it aimed to perform a gap analysis to 
identify areas where quality standards do not exist.
 Second, the EQUS study aimed to establish well-ac-
cepted and consensus-based minimal quality standards 
(MQS) for prevention, treatment, rehabilitation, and 
harm reduction in European countries based on this in-
ventory. The development of quality standards in drug 
prevention has been published earlier by our collaborat-
ing partners  [22] and was also integrated into the EQUS 
study  [23] .
 Methods 
 Framework of Quality Standards 
 The quality of an intervention in the EQUS study was deter-
mined according to the American Institute of Medicine  [2, 24] by 
(1) having the intended effects, (2) minimizing (acceptable) unin-
tended effects, and (3) making the best use of available resources. 
The quality of a service was determined by (1) having adequate 
resources, (2) having clear instructions for the staff to follow dur-
ing their daily routine and in special situations, (3) having a satis-
factory rate of positive outcomes, and (4) having a satisfactory ra-
tio between resources and the target population served. The qual-
ity of a system was determined by (1) complying with the legal and 
ethical framework in the respective country, (2) having satisfac-
tory systematised cooperation among services to satisfy the needs 
of the target populations, realise synergies and avoid unproductive 
conflict, (3) providing satisfactory coverage of the target popula-
tions in need of interventions, and (4) having a satisfactory ratio 
between resources and overall intervention effectiveness. 
 These factors are summarised under the headings of structural 
quality, process quality, and outcome quality for more than three 
decades  [24] . Structural quality involves personnel and physical 
requirements to perform services. Process quality covers dimen-
sions and aspects that are relevant for daily work in the different 
work areas that define a high professional standard. Outcome stan-
dards assess and inform about the effectiveness of interventions 
aiming at the well-being of the patient/client. All of these factors 
have to be regarded as dependent on each other and some overlap-
ping can occur  [24] .  Table  1 gives a systematic overview of the 
various subtypes of quality standards, according to the levels where 
they apply.
 Document Search 
 Members of the EQUS expert group were instructed to search 
for documents in their respective countries/languages and to 
screen them for information on quality standards. Therefore, de-
tailed instructions for the areas of treatment/rehabilitation and 
harm reduction were developed according to an initial proposal of 
the main authors, a pilot test and a finalisation of instructions in 
the EQUS expert group. Structured electronic Excel templates for 
the extraction and transmission of relevant information from the 
selected documents were developed. To avoid misunderstandings, 
manuals were developed for these two processes. The language of 
the documentation was English, and the translations from the doc-
uments into the templates were performed by the EQUS expert 
group, with special solutions for Central and Eastern European 
Countries (CEEC)  [23] .
 In addition, some relevant information was assessed:
 – the document source (literature review, expert opinion, expert 
consensus, research project, practice experience); 
 – the evidence grade (A: highest degree of evidence: review from 
multiple randomised controlled studies (RCTs) with conver-
gent results; B: moderate degree of evidence: prospective com-
parative longitudinal studies without control design; C: low de-
gree of evidence: single intervention/service follow-up studies, 
case studies; D: very low degree of evidence: non-systematic 
observations, and E: not known) adopted from the GRADE 
system for scientific evidence in medicine  [25] , and 
 – the level of obligation (mandatory vs. recommended) was as-
sessed during the completion of the templates.  
 Setting Up the Inventory 
 To set up the inventory, the following selection criteria were ap-
plied after careful discussion in the EQUS expert group: (1) pub-
lished documents were selected if they provided information on 
quality indicators and/or standards on specific interventions and/or 
specific settings and/or regional/national networks, (2) internation-
al documents were only selected if they were relevant at the nation-
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al level, (3) priority was given to official documents (e.g. by health 
authorities, professional associations, etc.), research reviews and re-
search reports, and (4) standards/guidelines that were exclusive to 
the drug field and not the broader healthcare field were included.
 To allow for a meaningful differentiation of standards for vari-
ous settings and interventions, the model design for standards in 
the fields of treatment/rehabilitation and for harm reduction was 
divided according to the chosen specification ( table 1 ). Moreover, 
a special category of ‘reference documents’ was created, as not all 
documents were equally important, with the following criteria: (1) 
it should be a national document, (2) it should have an evidence 
grade A or B for treatment/rehabilitation or an evidence grade A, 
B or C for harm reduction, and (3) it should be based on a system-
atic literature search or expert consensus.
 Descriptive statistics were calculated for preliminary compari-
sons of numbers of documents between structural, process and 
outcome standards. To compare numbers of documents per evi-
dence grade, the following weighting was applied for evidence 
grades: A = 4, B = 3, C = 2, D = 1, and E = 0 (no evidence). The gap 
analysis was performed qualitatively.
 Recruitment of Stakeholders for Survey Participation 
 Members of the EQUS expert group, national focal points from 
the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA), the World Health Organisation (WHO), and special 
advisers were invited to nominate relevant stakeholders for par-
ticipation in the survey  [23] , to inform the stakeholders of their 
nominations and to send their contact details to the Swiss Research 
Institute for Public Health and Addiction (ISGF), the coordinating 
research institute, in Zurich, Switzerland. They were further in-
structed to designate stakeholders who were health and social pro-
fessionals or representatives of public authorities, health insurers, 
user groups and church organisations. The online survey invita-
tion was sent directly from ISGF, together with an official invita-
tion letter from the director of the EU directorate-general justice.
 Online Survey Method 
 Between January and April 2011, two rounds of online surveys 
were undertaken to gather expert opinions on the proposed list of 
MQS selected from the inventory. The aim of the surveys was to 
assess expert opinion across the EU to determine the level of agree-
ment regarding the inclusion of particular standards ( tables 2,  3 ) 
in the final lists of minimum standards. The questionnaire asked 
about the acceptability of each standard and about any expected 
problems for implementation. The questionnaire was developed 
on the basis of feedback from the EQUS expert group and the 
EMCDDA’s Reitox Focal Points. A pilot version of the question-
naire given to the study partners resulted in a number of comments 
and improvements. Stakeholders were informed of the aim of the 
survey, that their answers would be processed anonymously, and 
that completion of the online survey would take approximately 
30–60 min of their time.
 In the first step, the stakeholders were asked to specify their 
names, the name of the country in which they mostly work, their 
main affiliation, job position, age, and main profession.
 The second step was to gather expert opinions on the accept-
ability of the quality standards derived from the inventory. To en-
able stakeholders to make informed decisions concerning the ac-
ceptability of each standard, they were provided with the following 
information: (1) the range of countries having mentioned the stan-
dard in guidelines or similar reference documents, (2) the available 
evidence grade, (3) the source of the information, and (4) the legal 
status of the standard. During the presentation of this information, 
the participants were asked to give a statement on the overall ac-
ceptability of a standard and a statement on the acceptability for 
different services and interventions in their country. Moreover, for 
each standard, the participants had to state the implementation 
status and feasibility of implementation in their country. 
 Initially, an online Delphi consensus process was intended. The 
level of consensus was remarkably high after the first round of test-
ing. However, not all of the European countries were represented, 
therefore the EQUS expert group decided to assess stakeholders 
from every European country, to foster participation in a later im-
plementation of the MQS. Thus, in the second round, the same 
survey was repeated with a broader recruitment strategy. 
 European Conference of Stakeholders 
 A European conference with participation by a wide range of 
different stakeholders was organised as an essential part of the con-
sensus-building process. This technical conference, hosted by the 
European Commission in association with the Hungarian Presi-
dency of the EU, was designed to bring together a range of stake-
holders to discuss the preliminary findings of the EQUS study. The 
conference took place in Brussels on June 15–17, 2011, and at-
tracted over 100 participants, including policy-makers, practi-
tioners, NGOs and researchers in the fields of drug prevention, 
treatment and harm reduction, from across the EU. The objectives 
of the conference included discussion of the proposed list of min-
imum quality standards according to the online survey ( tables 2 , 
 3 ) and outlooks on their implementation. 
Table 1.  Overview of possible types of quality standards according to Donabedian [24] and the Institute of Medicine [2]
Level 1: interventions Level 2: services Level 3: systems and policies
Structural quality Type of setting needed for implementation Resource standards Legal and ethical adequacy standards
Process quality Implementation standards Procedural standards Standards for networking and cooperation
among services
Outcome quality Effectiveness standards Effectiveness standards Coverage standards
Benchmarks Cost-benefit ratio Cost-utilisation ratio Cost-effectiveness ratio
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Table 2.  Treatment and rehabilitation standards investigated in the online expert survey
Draft number, group, description, and explanation of quality standard
Structural standards of services
TR1 Accessibility: location (service can easily be reached by public transport)
TR2 Physical environment: space (e.g. service has separate rooms for individual counselling)
TR3 Physical environment: safety (service is equipped for reanimation and other emergencies, e.g. management of 
overdose)
TR4 Indication criteria: diagnosis (treatment indication is always made on the basis of a diagnosis)
TR5 Staff composition: education (e.g. at least half of staff has a diploma in medicine, nursing, social work, or psychology)
TR6 Staff composition: transdisciplinarity (e.g. service employs a multidisciplinary team composed of at least 3 professions)
Process standards of services 
TRs7 Assessment procedures: substance use history, diagnosis and treatment history have to be assessed
TRs8 Assessment procedures: somatic status and social status have to be assessed
TRs9 Assessment procedures: psychiatric status has to be assessed
TRs10 Individualised treatment planning (treatment plans are tailored individually to the needs of the patient)
TRs11 Informed consent (patients must receive information on available treatment options and agree with a proposed 
regime or plan before starting treatment)
TRs12 Written client records (assessment results, intervention plan, interventions, expected changes and unexpected events 
are documented completely and updated for each patient in a patient record)
TRs13 Confidentiality of client data (patient records are confidential and exclusively accessible to staff involved in a patient’s 
treatment or regime)
TRs14 Routine cooperation with other agencies (whenever a service is not equipped to address all needs of a given patient, 
another appropriate service is available for referral)
TRs15 Continued staff training (staff is regularly updated on relevant new knowledge in their field of expertise)
Process standards of interventions (TRi) and services (TRs)
TRi7/TRs7 Assessment procedures: substance use history, diagnosis and treatment history have to be assessed
TRi8/TRs8 Assessment procedures: somatic status and social status have to be assessed
TRi9/TRs9 Assessment procedures: psychiatric status has to be assessed
TRi10/TRs10 Individualised treatment planning (treatment plans are tailored individually to the needs of the patient)
TRi11/TRs11 Informed consent (patients must receive information on available treatment options and agree with a proposed 
regime or plan before starting treatment)
TRi12/TRs12 Written client records (assessment results, intervention plan, interventions, expected changes and unexpected events 
are documented completely and updated for each patient in a patient record)
TRi13/TRs13 Confidentiality of client data (patient records are confidential and exclusively accessible to staff involved in a patient’s 
treatment or regime)
TRi14/TRs141 Routine cooperation with other agencies (whenever a service is not equipped to address all needs of a given patient, 
another appropriate service is available for referral)
TRi15/TRs151 Continued staff training (staff is regularly updated on relevant new knowledge in their field of expertise)
Outcome standards at the system level
TR16 Goal: health stabilisation/improvement (treatment must be aimed at improvement or stabilisation of health)
TR17 Goal: social stabilisation/integration (treatment must be aimed at improvement of social stabilisation or integration)
TR18 Goal: reduced substance use (treatment must be aimed at a reduction of substance use, e.g. helping the client/patient 
to reduce the use of or to abstain from psychotropic substances)
TR19 Utilisation monitoring (services must periodically report the occupancy of treatment slots or beds)
TR20 Discharge monitoring (e.g. ratio of regular/irregular discharges, retention rates, etc., have to be periodically monitored)
TR21 Internal evaluation (services must regularly perform an internal evaluation of their activities and outcomes)
TR22 External evaluation (services must regularly allow an evaluation of their activities and outcomes by an independent 
external evaluator)
TR231 Cost-effectiveness ratio (positive outcomes, e.g. number of abstinent patients in relation to treatment costs)
TR241 Cost-benefit ratio (tangible benefits, e.g. years of increased life expectancy in relation to treatment costs)
1 These MQS were excluded from the list after the conference.
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Table 3.  Harm reduction quality standards investigated in the online expert survey
Draft number, group, description, and explanation of quality standard
Structural standards of interventions
HR1 Accessibility: costs not to be paid by clients (exclusion of costs that limit the accessibility for poor clients/patients)
HR2 Accessibility: location (service can easily be reached by public transport)
HR3 Accessibility: opening hours (adjusted to the needs of clients/patients, e.g. evenings and weekends)
HR41 Staff qualification: minimal qualification (staff has to be qualified and the staff qualifications have to be made transparent, 
e.g. at least half of staff has a diploma in nursing or social work)
HR52 Staff composition: transdisciplinarity (e.g. service employs a multidisciplinary team composed of at least 2 professions)
HR61 Indication criteria: age limits [(1) services have to be age-appropriate and staff have to be trained to meet age-appropriate 
client’s needs, (2) there should be no age limits in harm reduction services]
HR72 Indication criteria: diagnosis (treatment indication is always made on the basis of a diagnosis or, if not possible, a detailed 
assessment of the current substance use)
Process standards of interventions
HR8 Assessment procedures: risk behaviour assessment (client’s/patient’s risk behaviour is assessed)
HR9 Assessment procedures: complete needs assessment and prioritisation [e.g. (1) harm reduction of intravenous drug use, and 
(2) reduction of used syringes in public spaces, etc.]
HR10 Assessment procedures: client/patient status (the client’s health status is assessed)
HR111 Informed consent (clients/patients must receive information on available service options and agree with a proposed regime 
or plan before starting an intervention. Interventions should not be based on written informed consent, but rather on 
transparent information regarding all the treatments offered by a service)
HR12 Confidentiality of client data (client/patient records are confidential and exclusively accessible to staff involved in a client’s/
patient’s intervention or regime)
HR132 Written client records (assessment results, intervention plan, interventions, expected changes and unexpected events are 
documented completely and updated for each client/patient in a client/patient record)
HR14 Individualised treatment planning (intervention regime and intervention plans, if applicable, are tailored individually to the 
needs of the client/patient)
HR15 Routine cooperation with other agencies (whenever a service is not equipped to address all needs of a given patient/client, 
another appropriate service is available for referral)
HR16 Continued staff training (staff is regularly updated on relevant new knowledge in their field of action)
HR17 Neighbourhood/community consultation (avoiding nuisance and conflict with other people around the service)
Outcome standards at system level
HR18 Goal: reduced risk behaviour (reducing unsafe injections, unsafe drug use and unprotected sex)
HR192 Goal: reduced substance use (treatment must be aimed at a reduction of substance use, e.g. helping the client/patient to 
reduce the use of or to abstain from psychotropic substances)
HR20 Goal: referrals (treatment services must be prepared to refer patients to other health/social/treatment services if needed and 
agreed)
HR21 Internal evaluation (services must regularly perform an internal evaluation of their activities and outcomes)
HR22 External evaluation (services must regularly allow an evaluation of their activities and outcomes by an independent external 
evaluator)
HR232 Utilisation monitoring (services must periodically report the occupancy of service slots)
HR242 Cost-effectiveness ratio (positive outcomes, e.g. number of abstinent patients in relation to service costs)
HR252 Cost-benefit ratio (tangible benefits, e.g. years of increased life expectancy in relation to service costs)
 1 These MQS were reformulated during the conference, reformulations are marked in italics. 2 These MQS were definitively exclud-
ed from the list after the conference.
HR1 – 3: these three standards were integrated into one MQS at the conference but were assessed separately in the online survey. HR6 
and HR7 were integrated into one MQS and reformulated at the conference as described in HR6 in the table.
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 Therefore, the proposed lists of minimum quality standards in 
the areas of treatment and harm reduction contained standards 
that reached high (>80%), moderate (>50–80%) or low degrees 
(<50%) of consensus in the online surveys. Those with high con-
sensus were presented for inclusion, those with moderate consen-
sus were discussed for eventual inclusion, and it was proposed that 
those with a low consensus on acceptability would be excluded 
from the MQS lists. If a given standard was considered to be ac-
ceptable, with the exception of specific settings or interventions, 
this acceptability was mentioned in the presented lists.
 Results 
 Inventory of Quality Standards 
 Overall, 564 documents were collected. Following a 
thorough review of the collected data, a total of 349 rele-
vant documents were identified. Of these, 259 (74.2%) 
documents were identified as pertaining to treatment and 
rehabilitation, and 90 (25.8%) pertained to harm reduc-
tion. Among those, 29 (8.3%) documents met the criteria 
for reference documents for treatment/rehabilitation and 
9 (2.6%) met the criteria for harm reduction reference 
documents.
 There were no major differences between the regional 
distributions applied for the document sources, but the 
document totals in treatment/rehabilitation differed con-
siderably more between the regions than those in the 
harm reduction category (for further details please visit 
the online supplementary tables; for all online suppl. ma-
terial, see www.karger.com/doi/10.1159/000350740).
 The resulting inventory contains a comprehensive list 
of quality standards and benchmarks emerging from the 
analysis of the templates ( tables 2 ,  3 ). In treatment/reha-
bilitation, the highest numbers of documents were identi-
fied in process standards (m = 82.0, SD = 23.7, median = 
84.0), followed by structural standards (m = 142.4, SD = 
20.7, median = 84.0) and outcome standards (m = 74.2, SD 
= 53.0, median = 57.0;  table 3 ). Similarly, the highest level 
of evidence was also found in process standards (m = 10.5, 
SD = 11.1, median = 9.0), whereas the levels of evidence in 
structural standards (m = 3.1, SD = 4.6, median = 2.5) and 
in outcome standards (m = 4.0, SD = 5.5, median = 3.0) 
were comparable in treatment/rehabilitation.
 The numbers of documents identified in harm reduc-
tion did not differ appreciably (process standards: m = 
28.9, SD = 9.1, median = 28.0; structural standards: m = 
23.4, SD = 6.9, median = 24.0; outcome standards: m = 
25.6, SD = 19.5, median = 22.5). Low levels of evidence 
were found in process standards (m = 1.6, SD = 2.3, me-
dian = 0.0) and outcome standards (m = 1.7, SD = 2.5, 
median = 0.0); even lower levels of evidence were found 
in structural standards (m = 0.9, SD = 1.5, median = 0.0) 
in harm reduction.
 Gap Analysis 
 In the inventory, we observed a lack of legal and ethical 
standards, coverage standards and economic standards 
(please visit the online suppl. tables at the journal website 
for more detailed information). Another gap existed in 
terms of available evidence for the proposed quality stan-
dards. There was a major deficit of documents that pro-
vide grades of evidence for specific standards; most stan-
dards were based on expert opinion and expert consensus 
or on literature reviews without having an evidence base. 
Among the treatment/rehabilitation standards, this was 
the case for most of the structural standards, for some 
outcome standards (treatment MQS number 17 (TR17), 
TR20) and especially for external evaluation (TR22). 
Among the harm reduction standards, there was no grade 
A or B evidence available for any structural standards 
(harm reduction MQS number 1 to 7 (HR1–HR7)), most 
process standards (HR8–HR17) or the economic stan-
dards of the outcome standards (HR23–HR25).
 Stakeholder Characteristics in the Online Surveys 
 In total, 241 (46.9%) of the 514 invited stakeholders 
participated in the two rounds of online surveys. Stake-
holders from all of the European countries except for Mal-
ta were represented. Stakeholder participants represented 
Northern (treatment/rehabilitation (TR): 21 participants; 
harm reduction (HR): 21 participants), Western and 
Southern (TR: 65; HR: 58), and Central and  Eastern Eu-
rope (TR: 53; HR: 44). Of the participating stakeholders, 
35.7% were from health and social affairs governmental 
organisations, 29.0% were from non- governmental or-
ganisations, 9.5% were from research groups/institutions, 
5.0% were from the private health sector, 3.7% were from 
justice and police governmental organisations, and 2.5% 
were from professional organisations. The majority of the 
survey participants were in a leading position (43.2%) or 
heads of their organisation (22.8%) and 23.2% were em-
ployees. The top five main professions represented (49.4% 
of the total participants) were psychiatrists (14.1%), psy-
chologists (11.6%), social workers (8.3%), public health 
staff (7.9%), and researchers (7.5%). 
 Consensus on the Proposed MQS 
 There was a high degree of consensus in the online 
survey regarding the proposed treatment/rehabilitation 
MQS (please visit the online suppl. tables for further re-
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sults at the journal website). The only two MQS with 
moderate consensus (>50–80%) that were discussed for 
inclusion at the conference were the cost-effectiveness 
ratio (TR23) and the cost-benefit ratio (TR24) as out-
come measures. The cost-effectiveness and cost-benefit 
standards were not included in the final treatment/reha-
bilitation MQS list as, at the conference, they were con-
sidered to be difficult to measure and that the results 
would be difficult to interpret. Accordingly, these stan-
dards were also the two MQS whose implementation re-
ceived the highest percentages of not feasible at all an-
swers (cost-effectiveness ratio: 22%, cost-benefit ratio: 
32%). The final list included 6 structural standards for 
interventions (TR1–6), 9 process standards for services 
(TRs7–15), 9 process standards for interventions (TRi7–
15), and 7 outcome standards (TR16–22). Those services 
that were listed as exceptions in the final list of 31 MQS 
were non-specialised teams (21 exceptions), prison-
based services (10 exceptions), and office-based services 
(10 exceptions).
 There was more disagreement in the harm reduction 
section of the survey. The three MQS on accessibility di-
mensions (HR1–3) were integrated in one new concept at 
the conference ( table 3 ). There was agreement that the 
inclusion of peers should also be taken into account in the 
standard pertaining to staff composition (HR5). The 
MQS on age limits (HR6) and indication criteria (HR7) 
were reformulated ( table 3 ). Moreover, the MQS on the 
confidentiality of informed consent (HR11) and client 
data (HR12) were also reformulated, and it was men-
tioned that the standard on referrals (HR15) should also 
include referrals to legal services. The MQS on utilisation 
monitoring (HR23) was dropped from the MQS list, al-
though it was proposed for inclusion according to the re-
sult of the online survey.
 The final list of harm reduction MQS included 3 struc-
tural standards of interventions (HR1–3 integrated into 
1 standard, HR4, HR6), 9 process standards (HR8–12, 
HR14–16), and 4 outcome standards (HR18, HR20–22).
 Implementation Status and Feasibility of 
Implementation 
 The best implemented treatment and rehabilitation 
MQS, according to the online survey, are staff composi-
tion/basic education (TR5, 47.9%), confidentiality of cli-
ent data (TRs13, 56.0%; TRi13, 60.0%), and assessment 
procedures for substance use history, diagnosis and treat-
ment (TRs7, 44.0%). The lowest implementation rates 
were found in the outcome standards of discharge moni-
toring (TR20, 14.8%), external evaluation (TR22, 7.8%), 
cost-effectiveness (TR23, 3.6%) and cost-benefit ratio 
(TR24, 2.2%). Most expected problems are reported from 
the MQS on service accessibility via public transport (TR1, 
38.6%), transdisciplinary staff composition (TR6, 41.3%), 
routine cooperation with other agencies (TRs14, 35.7%; 
TRi14, 49.1%), continued staff training (TRs, 40.5%; TRi, 
45.5%), discharge monitoring (TR20, 40.1%), and internal 
(TR21, 38.7%) and external evaluation (TR22, 53.2%).
 Generally, harm reduction MQS were less implement-
ed (mean percent (m%) = 24.4, standard deviation per-
cent (SD%) = 12.1 vs. m% = 32.8, SD% = 13.3) and were 
more frequently categorised as not feasible at all (m% = 
13.2, SD% = 7.4 vs. m% = 5.3, SD% = 6.9). The best imple-
mented harm reduction MQS were minimal staff qualifi-
cations (HR4, 35.5%), informed consent (HR11, 39.5%), 
reduced risk behaviour (HR18, 39.8%), and referrals to 
other services (HR20, 42.3%). Most expected problems 
were reported regarding the proposed harm reduction 
MQS on accessibility (HR2, access to public transport, 
44.9%; HR3, opening hours, 43.6%), routine cooperation 
with other agencies (HR15, 39.5%), continued staff train-
ing (HR16, 41.5%), and for almost all of the outcome 
standards. The most often expected problem categories 
were financial (treatment MQS: m% = 36.6, SD% = 13.5; 
harm reduction MQS: m% = 32.6, SD% = 13.7) and pro-
fessional (treatment MQS: m% = 25.7, SD% = 7.9; harm 
reduction MQS: m% = 20.1, SD% = 6.7). Political prob-
lems, although more frequent for harm reduction (treat-
ment MQS: m% = 7.3, SD% = 5.9; harm reduction MQS: 
m% = 11.0, SD% = 7.1), legal problems (treatment MQS: 
m% = 7.1, SD% = 4.7; harm reduction MQS: m% = 8.8, 
SD% = 5.2), and ethical problems (treatment MQS: 
m% = 6.1, SD% = 4.7; harm reduction MQS: m% = 7.8, 
SD% = 5.7) were explicitly less reported. 
 Discussion 
 The current study developed a comprehensive inven-
tory of existing standards, guidelines and other relevant 
documents on quality in treatment, rehabilitation, and 
harm reduction within the EU member states and at the 
international level. This inventory was screened for rele-
vance, and a gap analysis identified those areas where 
quality standards do not exist and where more develop-
ment and research on quality standards are needed. In 
a comprehensive consensus-building process, a list of 
 accepted treatment, rehabilitation and harm reduction 
MQS for European countries out of the inventory was 
developed, with detailed information on their implemen-
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tation status. Moreover, expected implementation prob-
lems have been identified.
 The inventory identified a lack of ethical and legal 
standards. A comprehensive list of ethical standards in 
terms of structural quality standards would include 
items related to professional competence and conduct 
in general, the rights and obligations of patients and 
staff, transparency of such rights and obligations, re-
sponsibility for services and information aimed at the 
general public  [26] . Future proposals for legal stan-
dards must be examined on the basis of international 
and national legislation as well as national documents 
on accreditation norms for services and specific inter-
ventions. Particularly in regard to non-clinical inter-
ventions, further legal guidance (‘research gover-
nance’) is needed. Although some legal standards are 
available (e.g. on child protection), there is a lack of 
prescriptive legal standards specifying what non-clin-
ical interventions and procedures are acceptable. Such 
standards are available for clinical interventions (e.g. 
governing the administration of methadone), but not 
for psychosocial interventions. 
 There is a paucity of documents that provide grades of 
evidence for specific standards; most standards are based 
on expert opinion, expert consensus or literature reviews 
without an evidence base.
 It is not surprising that there is less evidence for harm 
reduction standards for a number of reasons. Harm re-
duction interventions and services were developed later 
and less frequently than treatment and rehabilitation in-
terventions, although the number of documents did not 
substantially differ between regions. Moreover, research 
in the harm reduction field has concentrated on collect-
ing observational data rather than on creating experi-
mental designs. Additionally, research has focused more 
on evidence for the effectiveness of harm reduction ap-
proaches for specific objectives (e.g. the prevention of 
blood-borne infections  [27] ) than on the role of quality 
standards to be observed for specific intervention types or 
services. However, this type of evidence was not the focus 
of the EQUS study. The question was not whether recom-
mendations could be made for the availability of an inter-
vention or service based on relevant evidence, which 
would have been in line with the conceptualisation of 
guidelines  [28] , but rather which quality standards should 
be observed if a specific approach is made available in Eu-
ropean countries and those who consider joining the Eu-
ropean Union in the near future  [23] . The sense of qual-
ity standards is to help to implement chosen interven-
tions recommended in guidelines.
 The consensus-building process achieved already a 
high level of acceptance in the first round of the online 
survey of the proposed list of MQS, especially in the treat-
ment and rehabilitation section. This outcome persuaded 
the EQUS expert group to omit the planned Delphi con-
sensus method applied in other studies  [20] and to focus 
on increasing expert and stakeholder representation from 
all of the European countries. Exceptions regarding ac-
ceptability were observed for non-specialised teams and 
office-based services. In contrast, there was greater accep-
tance of prison-based services, and the MQS that were 
marked as exceptions were comprehensive. These find-
ings could help to foster the introduction of treatment 
standards in European prison services and highlight the 
overall acceptance of treatment standards for prison 
treatment services in countries where they have been in-
troduced or are in early development  [27] .
 The implementation of treatment and rehabilitation 
MQS has already progressed, with reported implementa-
tion ranging from 20 to 60%. Post hoc analyses revealed 
that higher implementation percentages have not been 
reached in Eastern European countries. Consequently, 
these countries should be provided with adequate funding 
and training to improve the implementation of the corre-
sponding MQS. Outcome quality and benchmark stan-
dards were rarely represented in the inventory of quality 
standards, in particular, the assessment of cost-effective-
ness and cost-benefit ratios was rejected and found to be 
not feasible at all for many services and interventions dur-
ing the consensus-building process. Thus, these standards 
should be handled with low priority, including in coun-
tries with high MQS implementation rates.
 As expected, the acceptance level for the proposed 
harm reduction MQS was less than the level of treatment 
and rehabilitation MQS. Political problems were more 
prevalent in the implementation of the harm reduction 
MQS than in the treatment and rehabilitation MQS. 
Nevertheless, the final MQS list is of special importance 
for harm reduction as it is likely to foster the introduc-
tion, further development, and research of quality stan-
dards in this comparatively newer area of drug demand 
reduction.
 Some important limitations merit consideration. The 
present lists of standards are not definite. It is expected 
that additional standards will be proposed in the future, 
for example on the continuity of care or on specific assess-
ment methods. Some EQUS standards could be more 
specific for special client/patient groups like for example 
those with severe dual diagnoses or for those young client 
groups that are hard to be reached by classical addiction 
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